Regenosca SA was incorporated in January 2019 (CH). We aim to develop and commercialize a new generation of biomaterials serving as an alternative to autologous tissue substitutes for soft tissue repair. Our materials are fabricated using a patented manufacturing technology. The resulting scaffolds stimulate the regeneration of functional tissue at the implanted site. Regenosca will bring unique benefits to all players in the health care customer chain: patients, surgeons, and hospitals.